Ifidancitinib

Catalog No. :
ACRKFZ419
CAS No. :
1236667-40-5
Molecular Formula :
C20H18FN5O3
Molecular Weight :
395.39

IUPAC Name:5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one

Ifidancitinib structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$215.00Login to see priceInquiryInquiry
10mg98%$349.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameIfidancitinib
IUPAC Name5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one
Molecular FormulaC20H18FN5O3
Molecular Weight395.39
SMILESO=C1OC2=CC=C(NC3=NC(NC4=CC(C)=C(F)C(OC)=C4)=NC=C3C)C=C2N1
InChI KeyOYFMQDVLFYKOPZ-UHFFFAOYSA-N
Synonym5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one | ifidancitinib | 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one | R105E71J13 | EX-A5899 | UNII-R1
CAS No.1236667-40-5
PubChem CID46851625

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACRKFZ419 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRKFZ419 route product structure diagram
    ACRKFZ4191236667-40-5
Inquiry

2. ACRKFZ419 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRKFZ419 route product structure diagram
    ACRKFZ4191236667-40-5
Inquiry

Comments (0)